233 related articles for article (PubMed ID: 19584260)
1. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of EGFR in malignant gliomas.
Ye F; Gao Q; Cai MJ
Expert Opin Ther Targets; 2010 Mar; 14(3):303-16. PubMed ID: 20148717
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.
Brandes AA; Franceschi E; Tosoni A; Hegi ME; Stupp R
Clin Cancer Res; 2008 Feb; 14(4):957-60. PubMed ID: 18281526
[TBL] [Abstract][Full Text] [Related]
5. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.
Chakravarti A; Dicker A; Mehta M
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):927-31. PubMed ID: 14967452
[TBL] [Abstract][Full Text] [Related]
6. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
7. Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
Karpel-Massler G; Wirtz CR; Halatsch ME
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):384-94. PubMed ID: 21612575
[TBL] [Abstract][Full Text] [Related]
8. Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents.
Nieder C; Grosu AL; Mehta MP; Andratschke N; Molls M
Expert Rev Neurother; 2004 Jul; 4(4):691-703. PubMed ID: 15853588
[TBL] [Abstract][Full Text] [Related]
9. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
[TBL] [Abstract][Full Text] [Related]
10. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas.
Viana-Pereira M; Lopes JM; Little S; Milanezi F; Basto D; Pardal F; Jones C; Reis RM
Anticancer Res; 2008; 28(2A):913-20. PubMed ID: 18507036
[TBL] [Abstract][Full Text] [Related]
11. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
Sonabend AM; Dana K; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
[TBL] [Abstract][Full Text] [Related]
12. Promising new therapies for malignant gliomas.
Fine HA
Cancer J; 2007; 13(6):349-54. PubMed ID: 18032970
[TBL] [Abstract][Full Text] [Related]
13. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
[TBL] [Abstract][Full Text] [Related]
15. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
[TBL] [Abstract][Full Text] [Related]
16. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
17. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.
Newton HB
Expert Rev Anticancer Ther; 2003 Oct; 3(5):595-614. PubMed ID: 14599084
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitors in children with malignant gliomas.
Herrington B; Kieran MW
Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.
Doherty L; Gigas DC; Kesari S; Drappatz J; Kim R; Zimmerman J; Ostrowsky L; Wen PY
Neurology; 2006 Jul; 67(1):156-8. PubMed ID: 16832099
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
Nicholas MK; Lukas RV; Jafri NF; Faoro L; Salgia R
Clin Cancer Res; 2006 Dec; 12(24):7261-70. PubMed ID: 17189397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
